Suppr超能文献

已形成肿瘤的T细胞介导的过继性免疫疗法的放射敏感屏障。

Radiosensitive barrier to T-cell-mediated adoptive immunotherapy of established tumors.

作者信息

Awwad M, North R J

机构信息

Trudeau Institute, Saranac Lake, New York 12983.

出版信息

Cancer Res. 1990 Apr 15;50(8):2228-33.

PMID:2317810
Abstract

This study shows that it is not possible to cause regression of the immunogenic SA-1 sarcoma by adoptive immunotherapy with tumor-sensitized T-cells, unless the tumor-bearing recipient is exposed to a sublethal dose of gamma-irradiation to remove a barrier that prevents adoptive immunity from being expressed. This barrier to adoptive immunotherapy was found to be regenerated between 2 and 4 weeks following irradiation, and its regeneration was associated with general repopulation of host T-cells. However, it was not regenerated in the absence of the thymus, thus showing that it is T-cell dependent. Evidence that it is caused by the presence of CD4+ suppressor T-cells was shown by the finding that it can be removed by depleting mice of CD4+ T-cells with anti-L3T4 monoclonal antibodies, but not by depleting them of CD8+ T-cells with anti-Lyt-2 monoclonal antibodies. Again, the barrier could be restored to irradiated recipients by infusing them with CD4+ T-cells, but not with CD8+ T-cells, from tumor-bearing donors. The barrier to adoptive immunotherapy was found to be tumor induced and to be paradoxically generated in concert with host concomitant immunity.

摘要

本研究表明,采用肿瘤致敏T细胞进行过继性免疫治疗不可能使免疫原性SA - 1肉瘤消退,除非荷瘤受体接受亚致死剂量的γ射线照射以消除阻止过继性免疫表达的屏障。发现这种过继性免疫治疗的屏障在照射后2至4周之间再生,其再生与宿主T细胞的总体再增殖有关。然而,在无胸腺的情况下它不会再生,因此表明它是T细胞依赖性的。有证据表明它是由CD4 +抑制性T细胞的存在引起的,这一发现表明,用抗L3T4单克隆抗体耗尽小鼠的CD4 + T细胞可消除该屏障,但用抗Lyt - 2单克隆抗体耗尽CD8 + T细胞则不能。同样,通过向受照射的受体输注来自荷瘤供体的CD4 + T细胞,而不是CD8 + T细胞,可使该屏障恢复。发现过继性免疫治疗的屏障是肿瘤诱导的,并且与宿主伴随免疫协同产生,这很矛盾。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验